NCT05170334View on ClinicalTrials.gov

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Metastatic Uveal Melanoma
Interventions
DRUG

Binimetinib

Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.

DRUG

Belinostat

Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

Sponsors
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Acrotech Biopharma Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER